According to the results of a study published in the Journal of the National Cancer Institute, osteosarcoma patients treated with the chemotherapy drugs cisplatin and doxorubicin every two weeks did not have better survival than patients who received the same drugs every three weeks.
In summary, this was one of the largest trials in osteosarcoma, and it tested the use of dose-intensified perioperative chemotherapy. Planned intensification of chemotherapy with cisplatin and doxorubicin increased received dose intensity and resulted in a statistically significant increase in favorable histologic response rate, but not in increased progression-free or overall survival
. Our results call into question the use of histologic response as a surrogate outcome measure in trials of this disease.Full study here
. Username is abcgroup
, password abcgroup
for all full research articles.